Recombinant Human MESDC2 Protein Summary
A recombinant protein with a N-Terminal His-tag and corresponding to the amino acids 34-234 of Human MESDC2
Source: E.coli
Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MAEGSPGTPD ESTPPPRKKK KDIRDYNDAD MARLLEQWEK DDDIEEGDLP EHKRPSAPVD FSKIDPSKPE SILKMTKKGK TLMMFVTVSG SPTEKETEEI TSLWQGSLFN ANYDVQRFIV GSDRAIFMLR DGSYAWEIKD FLVGQDRCAD VTLEGQVYPG KGGGSKEKNK TKQDKGKKKK EGDLKSRSSK EENRAGNKRE DL
E. coli
Recombinant Protein
MESDC2
>90%, by SDS-PAGE
Applications/Dilutions
24.9 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Packaging, Storage & Formulations
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
20mM Tris-HCl buffer (pH8.0) containing 20% glycerol, 0.1M NaCl, 1mM DTT
No Preservative
1 mg/ml
>90%, by SDS-PAGE
Alternate Names for Recombinant Human MESDC2 Protein
- BOCA
- KIAA0081Renal carcinoma antigen NY-REN-61
- MESDC2
- MESDLDLR chaperone MESD
- mesoderm development candidate 2Mesoderm development protein
Background
MESDC2, also known as Mesoderm development candidate 2, is required for formation of the primitive streak and mesoderm during embryogenesis. This protein binds to the Wnt co-receptors LRP5 and LRP6 in the endoplasmic reticulum and is required for their proper folding and cell surface expression. Recombinant human MESDC2 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.
product targets :　Keap1-Nrf9 inhibitors